Tsp Capital Management Group Lowers stake in Eli Lilly and Co (LLY)

Eli Lilly and Co (LLY) : Tsp Capital Management Group reduced its stake in Eli Lilly and Co by 0.14% during the most recent quarter end. The investment management company now holds a total of 73,134 shares of Eli Lilly and Co which is valued at $5,866,809 after selling 100 shares in Eli Lilly and Co , the firm said in a disclosure report filed with the SEC on Aug 10, 2016.Eli Lilly and Co makes up approximately 2.89% of Tsp Capital Management Group’s portfolio.

Other Hedge Funds, Including , Budros Ruhlin Roe reduced its stake in LLY by selling 982 shares or 3.62% in the most recent quarter. The Hedge Fund company now holds 26,139 shares of LLY which is valued at $2,096,871. Eli Lilly and Co makes up approx 0.69% of Budros Ruhlin Roe’s portfolio.Boston Family Office reduced its stake in LLY by selling 50 shares or 0.48% in the most recent quarter. The Hedge Fund company now holds 10,400 shares of LLY which is valued at $848,224. Eli Lilly and Co makes up approx 0.11% of Boston Family Office’s portfolio.Cadence Capital Management reduced its stake in LLY by selling 3,521 shares or 2.73% in the most recent quarter. The Hedge Fund company now holds 125,522 shares of LLY which is valued at $10,383,180. Eli Lilly and Co makes up approx 0.76% of Cadence Capital Management’s portfolio.1st Source Bank reduced its stake in LLY by selling 316 shares or 0.93% in the most recent quarter. The Hedge Fund company now holds 33,613 shares of LLY which is valued at $2,786,182. Eli Lilly and Co makes up approx 0.30% of 1st Source Bank’s portfolio.

Eli Lilly and Co closed down -0.72 points or -0.90% at $79.06 with 37,46,012 shares getting traded on Friday. Post opening the session at $79.55, the shares hit an intraday low of $78.78 and an intraday high of $79.79 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, Eli Lilly and Co reported $0.86 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $5404.80 million for the quarter, compared to analysts expectations of $5157.09 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 EPS.

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.

Leave a Reply

Eli Lilly and Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Eli Lilly and Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.